Skip to main content
Clinical Trials/NL-OMON36923
NL-OMON36923
Withdrawn
Not Applicable

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Injection of ABT-110 in Healthy Volunteers and Subjects with Chronic Low Back Pain - ABT-110 M12-143

Abbott0 sites30 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
chronic low back pain
Sponsor
Abbott
Enrollment
30
Status
Withdrawn
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Abbott

Eligibility Criteria

Inclusion Criteria

  • Healthy Volunteers: Male or female aged 18\-55 years; females must be postmenopausal or surgically sterilized; BMI between 18 and 29 inclusive; general good health.
  • CLBP Subjects: Male or female aged 18\-60 years; females must be postmenopausal or surgically sterilized; chronic pain located below 12th rib and above lower gluteal fold of at least 6 months duration and meeting protocol\-specified pain severity criteria; must be currently taking an NSAID, atypical analgesic (e.g. tramadol or tapentadol), or opioid analgesic for CLBP with inadequate analgesia.

Exclusion Criteria

  • Healthy Volunteers: Any clinically significant medical problems.
  • CLBP Subjects: Any radiation of pain below the lower gluteal fold; any back injury within 3 months prior to study drug; history of back surgery within 1 year prior to study drug; radiographic evidence (x\-ray) of osteoarthritis (OA) in any shoulder, hip or knee joint; history of osteonecrosis (avascular necrosis) or rapidly progressive OA in any joint; use of corticosteroids within the past year that meets protocol\-specified criteria.

Outcomes

Primary Outcomes

Not specified

Similar Trials